Exome sequencing reveals novel and recurrent mutations with clinical impact in blastic plasmacytoid dendritic cell neoplasm

Leukemia

Volumn 28, Issue 4, 2014, Pages 823-829

  Menezes, J ^a   Acquadro, F ^a,b   Wiseman, M ^b   Gomez Lopez G ^a   Salgado, R N ^a   Talavera Casanas J G ^c   Buno I ^d   Cervera, J V ^e   Montes Moreno, S ^f   Hernandez Rivas J M ^g   Ayala, R ^h   Calasanz, M J ⁱ   Larrayoz, M J ⁱ   Brichs, L F ^j   Gonzalez Vicent, M ^k   Pisano, D G ^a   Piris, M A ^f   Alvarez S ^a   Cigudosa, J C ^a  

^a Centro Nacional de Investigaciones Oncológicas   (Spain)

^b NIMGenetics   (Spain)

^c Servicio de Hematología y Hemoterapia Complejo Hospitalario Ntra   (Spain)

^d HOSPITAL GENERAL UNIVERSITARIO GREGORIO MARAÑÓN   (Spain)

^e HOSPITAL UNIVERSITARIO LA FE   (Spain)

^f HOSPITAL UNIVERSITARIO MARQUÉS DE VALDECILLA   (Spain)

^g UNIVERSITY OF SALAMANCA   (Spain)

^h HOSPITAL UNIVERSITARIO 12 DE OCTUBRE   (Spain)

ⁱ UNIVERSITY OF NAVARRA   (Spain)

^j HOSPITAL DEL MAR   (Spain)

^k HOSPITAL INFANTIL UNIVERSITARIO NIÑO JESÚS   (Spain)

more..

Author keywords

ASXL1; blastic NK cell lymphoma; BPDCN; IKAROS family; TET2

Indexed keywords

DNA METHYLTRANSFERASE 3A; UNTRANSLATED RNA;

ACUTE GRANULOCYTIC LEUKEMIA; ARTICLE; BLASTIC NK CELL LYMPHOMA; BLASTIC PLASMACYTOID DENDRITIC CELL NEOPLASM; BONE MARROW TUMOR; CANCER PROGNOSIS; CHROMATIN ASSEMBLY AND DISASSEMBLY; CLINICAL ARTICLE; CLINICAL FEATURE; DNA METHYLATION; EXOME; GENE; GENE MUTATION; GENE SEQUENCE; GENETIC SCREENING; HEMATOLOGIC MALIGNANCY; HOXB9 GENE; HUMAN; HUMAN TISSUE; IKZF3 GENE; LEUKEMOGENESIS; MUTATION RATE; OVERALL SURVIVAL; PLASMACYTOID DENDRITIC CELL; PRIORITY JOURNAL; RARE DISEASE; SOMATIC MUTATION; STOP CODON; TET2 GENE; UBE2G2 GENE; ZEB2 GENE;

DENDRITIC CELLS; DNA METHYLATION; DNA-BINDING PROTEINS; EXOME; HOMEODOMAIN PROTEINS; HUMANS; IKAROS TRANSCRIPTION FACTOR; LYMPHOMA, NON-HODGKIN; MUTATION; PROTO-ONCOGENE PROTEINS; REPRESSOR PROTEINS; SEQUENCE ANALYSIS, DNA;

EID: 84898037439     PISSN: 08876924     EISSN: 14765551     Source Type: Journal    
DOI: 10.1038/leu.2013.283     Document Type: Article

References (45)

1. Vardiman JW, Thiele J, Arber DA, Brunning RD, Borowitz MJ, Porwit A et al. The 2008 revision of the World Health Organization (WHO) classification of myeloid neoplasms and acute leukemia: rationale and important changes. Blood 2009; 114: 937-951.
2. Herling M, Jones D. CD4\+/CD56\+ hematodermic tumor: the features of an evolving entity and its relationship to dendritic cells. Am J Clin Pathol 2007; 127: 687-700.
3. Willemze R, Jaffe ES, Burg G, Cerroni L, Berti E, Swerdlow SH et al. WHO-EORTC classification for cutaneous lymphomas. Blood 2005; 105: 3768-3785. (Pubitemid 40656118)
4. Cella M, Jarrossay D, Facchetti F, Alebardi O, Nakajima H, Lanzavecchia A et al. Plasmacytoid monocytes migrate to inflamed lymph nodes and produce large amounts of type I interferon. Nat Med 1999; 5: 919-923. (Pubitemid 29372419)
5. Chaperot L, Bendriss N, Manches O, Gressin R, Maynadie M, Trimoreau F et al. Identification of a leukemic counterpart of the plasmacytoid dendritic cells. Blood 2001; 97: 3210-3217.
6. Petrella T, Comeau MR, Maynadie M, Couillault G, De Muret A, Maliszewski CR et al. 'Agranular CD4\+ CD56\+ hematodermic neoplasm' (blastic NK-cell lymphoma) originates from a population of CD56\+ precursor cells related to plasmacytoid monocytes. Am J Surg Pathol 2002; 26: 852-862. (Pubitemid 34752173)
7. Pilichowska ME, Fleming MD, Pinkus JL, Pinkus GS. CD4\+/CD56\+ hematodermic neoplasm ("blastic natural killer cell lymphoma"): neoplastic cells express the immature dendritic cell marker BDCA-2 and produce interferon. Am J Clin Pathol 2007; 128: 445-453. (Pubitemid 47479978)
8. Feuillard J, Jacob MC, Valensi F, Maynadie M, Gressin R, Chaperot L et al. Clinical and biologic features of CD4(\+)CD56(\+) malignancies. Blood 2002; 99: 1556-1563. (Pubitemid 34533026)
9. Petrella T, Bagot M, Willemze R, Beylot-Barry M, Vergier B, Delaunay M et al. Blastic NK-cell lymphomas (agranular CD4\+CD56\+ hematodermic neoplasms): a review. Am J Clin Pathol 2005; 123: 662-675. (Pubitemid 40586484)
10. Reichard KK, Burks EJ, Foucar MK, Wilson CS, Viswanatha DS, Hozier JC et al. CD4(\+) CD56(\+) lineage-negative malignancies are rare tumors of plasmacytoid dendritic cells. Am J Surg Pathol 2005; 29: 1274-1283. (Pubitemid 41368761)
11. Lee JK, Schiller G. Blastic plasmacytoid dendritic cell neoplasm. Clin Adv Hematol Oncol 2013; 10: 60-62.
12. Marafioti T, Paterson JC, Ballabio E, Reichard KK, Tedoldi S, Hollowood K et al. Novel markers of normal and neoplastic human plasmacytoid dendritic cells. Blood 2008; 111: 3778-3792.
13. Montes-Moreno S, Ramos-Medina R, Martinez-Lopez A, Barrionuevo Cornejo C, Parra Cubillos A, Quintana-Truyenque S et al. SPIB, a novel immunohistochemical marker for human blastic plasmacytoid dendritic cell neoplasms: characterization of its expression in major hematolymphoid neoplasms. Blood 2013; 121: 643-647.
14. Lucioni M, Novara F, Fiandrino G, Riboni R, Fanoni D, Arra M et al. Twenty-one cases of blastic plasmacytoid dendritic cell neoplasm: focus on biallelic locus 9p21.3 deletion. Blood 2011; 118: 4591-4594.
15. Jardin F, Ruminy P, Parmentier F, Troussard X, Vaida I, Stamatoullas A et al. TET2 and TP53 mutations are frequently observed in blastic plasmacytoid dendritic cell neoplasm. Br J Haematol 2011; 153: 413-416.
16. Reimer P, Rudiger T, Kraemer D, Kunzmann V, Weissinger F, Zettl A et al. What is CD4\+CD56\+ malignancy and how should it be treated? Bone Marrow Transplant 2003; 32: 637-646. (Pubitemid 37258618)
17. Assaf C, Gellrich S, Whittaker S, Robson A, Cerroni L, Massone C et al. CD56-positive haematological neoplasms of the skin: a multicentre study of the Cutaneous Lymphoma Project Group of the European Organisation for Research and Treatment of Cancer. J Clin Pathol 2007; 60: 981-989. (Pubitemid 47441929)
18. Dalle S, Beylot-Barry M, Bagot M, Lipsker D, Machet L, Joly P et al. Blastic plasmacytoid dendritic cell neoplasm: is transplantation the treatment of choice? Br J Dermatol 2010; 162: 74-79.
19. Roos-Weil D, Dietrich S, Boumendil A, Polge E, Bron D, Carreras E et al. Stem cell transplantation can provide durable disease control in blastic plasmacytoid dendritic cell neoplasm: a retrospective study from the European Group for Blood and Marrow Transplantation. Blood 2013; 121: 440-446.
20. Rubio-Camarillo M, Gomez-Lopez G, Fernandez JM, Valencia A, Pisano DG. RUbioSeq: a suite of parallelized pipelines to automate exome variation and bisulfite-seq analyses. Bioinformatics 2013; 29: 1687-1989.
21. Li H, Durbin R. Fast and accurate short read alignment with Burrows-Wheeler transform. Bioinformatics 2009; 25: 1754-1760.
22. Homer N, Merriman B, Nelson SF. BFAST: an alignment tool for large scale genome resequencing. PLoS One 2009; 4: e7767.
23. DePristo MA, Banks E, Poplin R, Garimella KV, Maguire JR, Hartl C et al. A framework for variation discovery and genotyping using next-generation DNA sequencing data. Nat Genet 2011; 43: 491-498.
24. Jones S, Wang TL, Shih IeM, Mao TL, Nakayama K, Roden R et al. Frequent mutations of chromatin remodeling gene ARID1A in ovarian clear cell carcinoma. Science 2010; 330: 228-231.
25. McLaren W, Pritchard B, Rios D, Chen Y, Flicek P, Cunningham F. Deriving the consequences of genomic variants with the Ensembl API and SNP Effect Predictor. Bioinformatics 2010; 26: 2069-2070.
26. Fernandez-Mercado M, Yip BH, Pellagatti A, Davies C, Larrayoz MJ, Kondo T et al. Mutation patterns of 16 genes in primary and secondary acute myeloid leukemia (AML) with normal cytogenetics. PLoS One 2012; 7: e42334.
27. Cancer Genome Atlas Research Network. Genomic and epigenomic landscapes of adult de novo acute myeloid leukemia. N Engl J Med 2013; 368: 2059-2074.
28. Abdel-Wahab O, Manshouri T, Patel J, Harris K, Yao J, Hedvat C et al. Genetic analysis of transforming events that convert chronic myeloproliferative neoplasms to leukemias. Cancer Res 2010; 70: 447-452.
29. Tefferi A. Novel mutations and their functional and clinical relevance in myeloproliferative neoplasms: JAK2, MPL, TET2, ASXL1, CBL, IDH and IKZF1. Leukemia 2010; 24: 1128-1138.
30. Mardis ER, Ding L, Dooling DJ, Larson DE, McLellan MD, Chen K et al. Recurring mutations found by sequencing an acute myeloid leukemia genome. N Engl J Med 2009; 361: 1058-1066.
31. Ley TJ, Miller C, Ding L, Raphael BJ, Mungall AJ, Robertson A et al. Genomic and epigenomic landscapes of adult de novo acute myeloid leukemia. N Engl J Med 2013; 368: 2059-2074.
32. Holmfeldt L, Wei L, Diaz-Flores E, Walsh M, Zhang J, Ding L et al. The genomic landscape of hypodiploid acute lymphoblastic leukemia. Nat Genet 2013; 45: 242-252.
33. Caudell D, Harper DP, Novak RL, Pierce RM, Slape C, Wolff L et al. Retroviral insertional mutagenesis identifies Zeb2 activation as a novel leukemogenic collaborating event in CALM-AF10 transgenic mice. Blood 2010; 115: 1194-1203.
34. Shih AH, Abdel-Wahab O, Patel JP, Levine RL. The role of mutations in epigenetic regulators in myeloid malignancies. Nat Rev Cancer 2012; 12: 599-612.
35. Metzeler KH, Maharry K, Radmacher MD, Mrozek K, Margeson D, Becker H et al. TET2 mutations improve the new European LeukemiaNet risk classification of acute myeloid leukemia: a Cancer and Leukemia Group B study. J Clin Oncol 2011; 29: 1373-1381.
36. Bejar R, Stevenson K, Abdel-Wahab O, Galili N, Nilsson B, Garcia-Manero G et al. Clinical effect of point mutations in myelodysplastic syndromes. N Engl J Med 2011; 364: 2496-2506.
37. Tefferi A, Pardanani A, Lim KH, Abdel-Wahab O, Lasho TL, Patel J et al. TET2 mutations and their clinical correlates in polycythemia vera, essential thrombocythemia and myelofibrosis. Leukemia 2009; 23: 905-911.
38. Green CL, Evans CM, Hills RK, Burnett AK, Linch DC, Gale RE. The prognostic significance of IDH1 mutations in younger adult patients with acute myeloid leukemia is dependent on FLT3/ITD status. Blood 2010; 116: 2779-2782.
39. Green CL, Evans CM, Zhao L, Hills RK, Burnett AK, Linch DC et al. The prognostic significance of IDH2 mutations in AML depends on the location of the mutation. Blood 2011; 118: 409-412.
40. Tefferi A, Jimma T, Sulai NH, Lasho TL, Finke CM, Knudson RA et al. IDH mutations in primary myelofibrosis predict leukemic transformation and shortened survival: clinical evidence for leukemogenic collaboration with JAK2V617F. Leukemia 2012; 26: 475-480.
41. Ley TJ, Ding L, Walter MJ, McLellan MD, Lamprecht T, Larson DE et al. DNMT3A mutations in acute myeloid leukemia. N Engl J Med 2010; 363: 2424-2433.
42. Yan XJ, Xu J, Gu ZH, Pan CM, Lu G, Shen Y et al. Exome sequencing identifies somatic mutations of DNA methyltransferase gene DNMT3A in acute monocytic leukemia. Nat Genet 2011; 43: 309-315.
43. Walter MJ, Ding L, Shen D, Shao J, Grillot M, McLellan M et al. Recurrent DNMT3A mutations in patients with myelodysplastic syndromes. Leukemia 2011; 25: 1153-1158.
44. James LI, Frye SV. Targeting chromatin readers. Clin Pharmacol Ther 2013; 93: 312-314.
45. Burridge S. Target watch: drugging the epigenome. Nat Rev Drug Discov 2013; 12: 92-93.